CRISPR Therapeutics (CRSP) Reports $116M FY25 Revenue Driven by CASGEVY Growth.
Share this article
Earnings
Score 82
Bullish
CRISPR Therapeutics (CRSP) Reports $116M FY25 Revenue Driven by CASGEVY Growth
Mar 11, 2026 20:56 UTC
CRSP, XLV, IHI
Short term
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.